Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
Ardelyx (ARDX)
NASDAQ:ARDX
Holding ARDX?
Track your performance easily
ARDX Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$3.16 - $10.13
Previous Close$5.9
Volume997.37K
Average Volume (3M)4.16M
Market Cap
$1.44B
Enterprise Value$1.31B
Total Cash (Recent Filing)$185.96M
Total Debt (Recent Filing)$104.89M
Price to Earnings (P/E)―
Beta1.06
Next Earnings
Nov 07, 2024EPS Estimate
-$0.05Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.28
Shares Outstanding235,428,183
10 Day Avg. Volume2,418,894
30 Day Avg. Volume4,162,304
Standard Deviation0.23
R-Squared0.04
Alpha0.03
Financial Highlights & Ratios
Price to Book (P/B)9.52
Price to Sales (P/S)6.89
Price to Cash Flow (P/CF)-18.70
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/Revenue6.23
Enterprise Value/Gross Profit12.26
Enterprise Value/Ebitda-28.09
Forecast
1Y Price Target
$10.79Price Target Upside76.31% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering7
Ardelyx News
Bulls Say, Bears Say
Bulls Say
Financial PerformanceArdelyx reported a 2Q24 total revenues top line beat of $73.2M (~59% increase Q/Q), which was ~33%/~32% above FactSet consensus/analyst estimates, exhibiting strong growth for both Ibsrela in IBS-C and, particularly, their newer launched product Xphozah for hyperphosphatemia.
Product LaunchThe Xphozah launch continued to show strong momentum, with 2Q24 Xphozah revenues of $37.1M coming in significantly above consensus/analyst estimates.
Sales Force ExpansionThe expansion to a 124 sales rep field force for Ibsrela is nearing completion, and more tangible benefit is expected to manifest later in the second half of the year.
Bears Say
Commercial UncertaintyThe decision to forego the TDAPA program for Xphozah significantly increases commercial risk and restricts patient access.
Legal IssuesArdelyx's lawsuit against the CMS is expected to create significant legal expenses and management distraction, potentially leading to uncertainty around the stock.
Reimbursement IssuesCMS is now signaling its intent to severely restrict access to Xphozah, creating concerns about the drug's commercial viability.
---
Risk Analysis
Main Risk Category
Legal & RegulatoryLitigation, compliance, new legislation, and taxation risks
ARDX FAQ
What was Ardelyx’s price range in the past 12 months?
Ardelyx lowest stock price was $3.16 and its highest was $10.13 in the past 12 months.
What is Ardelyx’s market cap?
Currently, no data Available
When is Ardelyx’s upcoming earnings report date?
Ardelyx’s upcoming earnings report date is Nov 07, 2024 which is in 48 days.
How were Ardelyx’s earnings last quarter?
Ardelyx released its earnings results on Aug 01, 2024. The company reported -$0.07 earnings per share for the quarter, beating the consensus estimate of -$0.106 by $0.036.
Is Ardelyx overvalued?
According to Wall Street analysts Ardelyx’s price is currently Undervalued.
Does Ardelyx pay dividends?
Ardelyx does not currently pay dividends.
What is Ardelyx’s EPS estimate?
Ardelyx’s EPS estimate is -$0.05.
How many shares outstanding does Ardelyx have?
Ardelyx has 235,428,180 shares outstanding.
What happened to Ardelyx’s price movement after its last earnings report?
Ardelyx reported an EPS of -$0.07 in its last earnings report, beating expectations of -$0.106. Following the earnings report the stock price went up 10%.
Which hedge fund is a major shareholder of Ardelyx?
Among the largest hedge funds holding Ardelyx’s share is Oracle Investment Management Inc. It holds Ardelyx’s shares valued at 11M.
---
Ardelyx Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$10.79 (76.31% Upside)
$10.79 (76.31% Upside)
Blogger Sentiment
Bullish
ARDX Sentiment 96%
Sector Average 70%
Sector Average 70%
Hedge Fund Trend
Decreased
By 390.4K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $520.2K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Negative
Last 7 Days ▼ 2.0%
Last 30 Days ▼ 5.5%
Last 30 Days ▼ 5.5%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
41.48%
12-Months-Change
Fundamentals
Return on Equity
-48.23%
Trailing 12-Months
Asset Growth
62.63%
Trailing 12-Months
Company Description
Ardelyx
Ardelyx, Inc. is a biopharmaceutical company, which engages in the research, development and commercialization of medicine for the treatment of renal diseases. It focuses on the formulation of programs directed toward treating gastrointestinal and irritable bowel syndrome with constipations. Its product portfolio includes tenapanor, which is an experimental medication that works exclusively in the gut and is in late-stage clinical development. The company was founded by Dominique Charmot, Peter G. Schultz, and Jean M. Frechet on October 17, 2007 and is headquartered in Fremont, CA.
---
ARDX Earnings Call
Q2 2024
0:00 / 0:00
---
ARDX Stock 12 Month Forecast
Average Price Target
$10.79
▲(76.31% Upside)
Technical Analysis
Aurinia Pharmaceuticals
―
Fennec Pharmaceuticals
―
Karyopharm Therapeutics
―
Arrowhead Pharmaceuticals
―
Best Analysts Covering ARDX
1 Year
1 Year Success Rate
4/7 ratings generated profit
1 Year Average Return
+9.84%
reiterated a buy rating 3 months ago
Copying Matthew Kaplan's trades and holding each position for 1 Year would result in 57.14% of your transactions generating a profit, with an average return of +9.84% per trade.
---